“Not all forms of NAFLD were created equal”. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?

Atherosclerosis

Volumn 257, Issue , 2017, Pages 253-255

  Lonardo, Amedeo ^a   Ballestri, Stefano ^b   Targher, Giovanni ^c  

^a Nuovo Ospedale S Agostino   (Italy)

^b AUSL Modena   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Atherosclerosis; Carotid; Genetic polymorphisms; Insulin resistance; Metabolic syndrome; NAFLD

Indexed keywords

PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PROTEIN; UNCLASSIFIED DRUG;

ARTERIAL WALL THICKNESS; BLOOD DONOR; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CORONARY ARTERY OBSTRUCTION; ECHOGRAPHY; EDITORIAL; FAT CONTENT; FATTY LIVER; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE;

ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; HUMANS; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85010223702     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2017.01.008     Document Type: Editorial

References (20)

1. [1] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease. Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
2. [2] Byrne, C.D., Targher, G.N.A.F.L.D., A multisystem disease. J. Hepatol. 62:1 Suppl (2015), S47–S64.
3. [3] Lonardo, A., Sookoian, S., Chonchol, M., Loria, P., Targher, G., Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr. Pharm. Des. 19 (2013), 5177–5192.
4. [4] Yki-Järvinen, H., Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2 (2014), 901–910.
5. [5] Anstee, Q.M., Day, C.P., The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin. Liver Dis. 35 (2015), 270–290.
6. [6] Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H., Grieco, A., Machado, M.V., Miele, L., Targher, G., Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. Liver Dis. 47 (2015), 997–1006.
7. [7] Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., Roverato, A., Guaraldi, G., Lonardo, A., Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31 (2016), 936–944.
8. [8] Di Costanzo, A., D'Erasmo, L., Polimeni, L., Baratta, F., Coletta, P., Di Martino, M., Loffredo, L., Perria, L., Ceci, F., Montali, A., Girelli, G., De Masi, B., Angeloni, A., Catalano, C., Maranghi, M., Del Ben, M., Angelico, F., Arca, M., Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis, 2016 Dec 21 pii: S0021-9150(16) 31539–8.
9. [9] Lonardo, A., Ballestri, S., Targher, G., Loria, P., Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 9 (2015), 629–650.
10. [10] Petta, S., Valenti, L., Marchesini, G., Di Marco, V., Licata, A., Cammà, C., Barcellona, M.R., Cabibi, D., Donati, B., Fracanzani, A., Grimaudo, S., Parrinello, G., Pipitone, R.M., Torres, D., Fargion, S., Licata, G., Craxì, A., PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoSOne, 8, 2013, e74089.
11. [11] Posadas-Sánchez, R., López-Uribe, Á.R., Posadas-Romero, C., Pérez-Hernández, N., Rodríguez-Pérez, J.M., Ocampo-Arcos, W.A., Fragoso, J.M., Cardoso-Saldaña, G., Vargas-Alarcón, G., Association of the I148M/PNPLA3 (rs738409) polymorphism with premature coronary artery disease, fatty liver, and insulin resistance in type 2 diabetic patients and healthy controls. The GEA study. Immunobiology, 2016 Sep 3, 10.1016/j.imbio.2016.08.008 pii: S0171-2985(16)30355-2.
12. [12] Xia, M.F., Ling, Y., Bian, H., Lin, H.D., Yan, H.M., Chang, X.X., Li, X.M., Ma, H., Wang, D., Zhang, L.S., Wang, S.S., Wu, B.J., He, W.Y., Zhao, N.Q., Gao, X., I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment. PharmacolTher 43 (2016), 631–642.
13. [13] Lonardo, A., Ballestri, S., Guaraldi, G., Nascimbeni, F., Romagnoli, D., Zona, S., Targher, G., Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV. World J. Gastroenterol. 22 (2016), 9674–9693.
14. [14] Oni, E.T., Agatston, A.S., Blaha, M.J., Fialkow, J., Cury, R., Sposito, A., Erbel, R., Blankstein, R., Feldman, T., Al-Mallah, M.H., Santos, R.D., Budoff, M.J., Nasir, K., A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 230 (2013), 258–267.
15. [15] Mellinger, J.L., Pencina, K.M., Massaro, J.M., Hoffmann, U., Seshadri, S., Fox, C.S., O'Donnell, C.J., Speliotes, E.K., Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J. Hepatol. 63 (2015), 470–476.
16. [16] Wolff, L., Bos, D., Murad, S.D., Franco, O.H., Krestin, G.P., Hofman, A., Vernooij, M.W., van der Lugt, A., Liver fat is related to cardiovascular risk factors and subclinical vascular disease: the Rotterdam Study. Eur. Heart J. Cardiovasc Imaging 17 (2016), 1361–1367.
17. [17] Sinn, D.H., Kang, D., Chang, Y., Ryu, S., Gu, S., Kim, H., Seong, D., Cho, S.J., Yi, B.K., Park, H.D., Paik, S.W., Song, Y.B., Lazo, M., Lima, J.A., Guallar, E., Cho, J., Gwak, G.Y., Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 66 (2017), 323–329, 10.1136/gutjnl-2016-311854.
18. [18] Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., Barbui, C., Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 65 (2016), 589–600.
19. [19] Lonardo, A., Lombardini, S., Scaglioni, F., Carulli, L., Ricchi, M., Ganazzi, D., Adinolfi, L.E., Ruggiero, G., Carulli, N., Loria, P., Hepatic steatosis and insulin resistance: does etiology make a difference?. J. Hepatol., 44, 2006 190–196.20.
20. [20] Oniki, K., Saruwatari, J., Izuka, T., Kajiwara, A., Morita, K., Sakata, M., Otake, K., Ogata, Y., Nakagawa, K., Influence of the PNPLA3 rs738409 polymorphism on nonalcoholic fatty liver disease and renal function among normal weight subjects. PLoS One, 10, 2015, e0132640.